Market evolution: Female sex hormones (CN 293723) — 2015–2025

Introduction

This report analyses the evolution of EU trade in oestrogens and progestogens (CN 293723) between 2015 and 2025. The period was marked by significant structural shifts: the EU transformed from a net importer to a net exporter, while import volumes surged and prices fell. The analysis is based on the provided trade data and covers trade flows, partner dynamics, and the EU's strategic position.

1. Volume Surge and Price Compression: The Import-Led Transformation

The decade was defined by a dramatic expansion of import volumes into the EU, occurring alongside a sustained fall in average unit prices. This dynamic fundamentally reshaped the EU's trade balance for this product category.

Import volumes grew exponentially, far outpacing exports

Between 2015 and 2025, EU imports of oestrogens and progestogens saw their quantity increase by 221.7%, rising from 156.5 tonnes to 503.4 tonnes. In contrast, export quantities grew by 57.3% over the same period, reaching 98.7 tonnes. This volume disparity is the primary driver of the trade balance's shift.

Steep price declines indicate a commoditizing market

The surge in volumes was accompanied by a sharp decline in average prices. The import price (EUR per tonne) fell by 56.3% from €935,092 to €408,478. Export prices also decreased, albeit less dramatically, by 15.8% to €1.85 million per tonne. This price compression suggests increased competition, potential oversupply from major producing regions, or a shift in the product mix towards lower-value segments within the code.

The trade balance swung from deficit to surplus

The EU's trade balance in value terms flipped from a deficit of €5.8 million in 2015 to a surplus of €23.4 million in 2025. This turnaround, despite the massive import volume growth, was achieved because the value of EU exports grew slightly more than the value of imports, thanks to the higher unit value of exported products.

2. Geographic Reorientation and Shifting Concentrations

The sources of EU imports and the destinations of its exports underwent notable changes, leading to increased supplier concentration on the import side.

Asian suppliers, especially China and India, consolidated their dominance

China remained the EU's largest import partner, with trade value increasing by 66.2%. India's role expanded dramatically, with its export value to the EU growing by 287.3%. Conversely, imports from traditional partners like the United States, Canada, and Hong Kong collapsed, indicating a strategic shift in EU sourcing towards large-scale Asian producers.

Import concentration rose while export markets diversified

The Herfindahl-Hirschman Index (HHI) for imports increased by 19.9%, pointing to greater reliance on a narrower set of suppliers. In contrast, the HHI for exports remained stable (-0.4%), reflecting the EU's ability to maintain a diversified customer base, with significant growth in shipments to the UK, Switzerland, India, and even Russia.

Certain trade flows exhibited extreme volatility

Analysis of coefficient of variation (CV) reveals that some trade relationships were highly unstable. Notably, EU imports from Hong Kong (CV 1.78) and Canada (CV 1.37) displayed very high volatility. On the export side, shipments to the UK (CV 1.16) and Morocco (CV 1.49) were similarly erratic, highlighting the precariousness of certain bilateral flows.

3. Strategic Shift: The EU's Evolving Production and Export Capacity

The period saw the EU's position evolve, underpinned by changes in its own production landscape and a strengthening of its export orientation within the global market.

Net import reliance reversed, signaling a strategic shift

The most striking structural change was the EU's net import reliance percentage swinging from +64.3% in 2015 to -34.9% in 2025. This move into negative territory confirms the EU transitioned from being a net importer to a net exporter in value terms, despite still importing vastly larger physical volumes. This indicates a focus on higher-value-added exports.

EU production data suggests massive scale-up, though data quality warrants caution

The reported EU production quantity grew by an extraordinary 6,364.9% (in gross tonnage) over the period. While such a figure should be interpreted with caution due to potential data reporting changes, it aligns with the observed surge in import volumes for processing and the growth in high-value exports. Italy, Belgium, and the Netherlands emerged as the most specialised EU producers.

Export propensity strengthened as the EU focused on global markets

The EU's export propensity (the share of production that is exported) increased by 22.1%, reaching 73.3%. This indicates that a growing portion of the EU's output was directed towards international markets. At the same time, overall trade intensity (the sum of imports and exports as a share of apparent consumption) slightly decreased, suggesting a degree of market maturation or increased domestic absorption.

Conclusion

Over the 2015–2025 period, the EU trade landscape for oestrogens and progestogens was fundamentally reshaped. The region became a major importer of lower-priced active ingredients, primarily from Asia, while simultaneously building a strong export business for what appears to be higher-value finished or intermediate products. This strategic pivot is evidenced by the EU becoming a net exporter in value terms, the growth of its export propensity, and the specialised production bases in member states like Italy and Belgium. The key risks remain the high volatility of certain bilateral flows and the increasing concentration of import sources. The data points to a mature, globally integrated EU pharmaceutical chemical sector that leverages global supply chains for raw materials while competing effectively on the export market.